Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
- Friday, June 3, 2022, 7:10
- Business
- Add a comment
Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and high doses Low dose IHL-42X reduced AHI by an average of 50.7% compared to baseline with…
About the Author
adminasapcorp has written 41532 stories on this site.